Purposeful is a biotech company, integrating AI and human expertise to accelerate the development of rare disease treatments.
Our aim is to discover additional uses for existing drugs.
We solve the problem of crippling costs associated with drug development by predicting additional effects of compounds already on the market, thus minimizing the number of experiments necessary to carry out before reaching a promising candidate.
Meet the team
Complementary expertise and positive team attitude make us stronger.
George Drakakis
CEO
Charalampos Chomenidis
CTO
Georgia Tsiliki
COO
Aris Dokoumetzidis
Scientific Advisor
Thalia Vlachou
Biomedical Scientist
George Drakakis
CEO
George is the CEO of Purposeful. He loves solving problems, especially when there is a clear impact in the life sciences. George has worked in the area of Cheminformatics since 2011. During his PhD at the University of Cambridge, he worked on applied modelling and mechanism of action elucidation in small molecules. After almost four years of postdoctoral research in the fields of chemo- and nanoinformatics, he decided that it was time to put this experience to the test, by co-founding Purposeful.
Charalampos Chomenidis
CTO
Charalampos is co-founder and CTO of Purposeful. He has industry experience on many modern programming languages, frameworks and database systems, and is actively involved on cutting edge software technologies, from AI and IoT to Blockchain systems. His greatest passion is good software design, and always advocates the use of design patterns and best practices in coding and software architecture. He has also worked as a research associate in the field of Applied Machine Learning, with several publications under his belt. When not coding or designing software, Charalampos plays the double bass in a Jazz Trio, or records tracks in his personal studio.
Georgia Tsiliki
COO
Georgia is the COO and a co-founder of Purposeful. She is passionate about organizing and exploring data to improve original assumptions. Her research interests lie in the area of biomedical statistical analysis, bioinformatics and chemoinformatics, ranging from theory to design and implementation. She has extensive experience on integrating omics data and chemo-related data for a better understanding of the mechanisms of action for compounds, drugs and nanomaterials. She has worked as a researcher for more than ten years and has collaborated actively with biology and medicine specialists. Georgia received her PhD in Statistics from Imperial College London.
Aris Dokoumetzidis
Scientific Advisor
Aris is co-founder of Purposeful and currently has the role of Scientific Advisor in the company. He is also an Associate Professor of Pharmacometrics in the Department of Pharmacy of the University of Athens. His expertise is mathematical modelling & simulation in drug development and clinical pharmacology. In the past he has worked as a lecturer at Queen’s University Belfast and as researcher at the University of Manchester. He has had many collaborations as a consultant for the pharmaceutical industry while he has served for 5 years as a member of the Modelling and Simulation Working Party of the European Medicines Agency.
Thalia Vlachou
Biomedical Scientist
Thalia is a Biomedical Scientist at Purposeful. She has more than 10 years of experience as experimentalist in biomedical research, primarily in the field of Molecular Oncology. She studied Biology at the University of Athens, earned her MSc from King’s College London and completed her PhD at the European Institute of Oncology (IEO) in Milan. She has expertise in systems biology approaches, molecular and cell biology, cancer genomics, single-cell and single-molecule transcriptomics. She is passionate about innovation, drug discovery and bringing healthcare solutions to the people who need it the most. She strongly believes in multidisciplinary approaches and has a record of fruitful collaborations with clinicians, computational scientists and statisticians.
Advisory Board
Patricia Cogram, PhD
Principal Investigator IEB, University of Chile
Wielfried Langenaeker, PhD
Senior Consultant, Janssen Pharmaceutical
Patricia Cogram, PhD
Principal Investigator IEB, University of Chile
Patricia Cogram, Ph.D., is an Associate Professor of Genetics at the IEB Genetics Department, University of Chile. She graduated at University College London, BSc in Evolutionary genetics and MSc in Neuroscience at Oxford University, UK. Dr Cogram received a Ph.D. in Neurodevelopment at University College London, UK and conducted postdoctoral studies at the Medical Research Council, UK and UCL. Patricia is a leading researcher in the field of neurodevelopmental rare diseases. Dr. Cogram has over 20 years of experience in drug discovery. As the Director of the Biomedicine Division at Fraunhofer-Gesellschaft Research Laboratories, she led several programs on neuroinflammation and rare diseases to the pipeline of different Pharma Corporations. She is also the CEO of GeN Ltd a biotechnology company dedicated to disease target identification and drug development in PTHS, FXS and other forms of Autism.
Wielfried Langenaeker, PhD
Senior Consultant, Janssen Pharmaceutical